Key Quantitative Figures - Quarterly Performance (Q2 FY27)

  • Revenue from operations: ₹1,951.01 crore (Q2 FY26: ₹1,757.15 crore)
  • Total Income: ₹2,019.07 crore (Q2 FY26: ₹1,827.10 crore)
  • Profit before tax: ₹610.47 crore (Q2 FY26: ₹545.93 crore)
  • Total tax expenses: ₹157.02 crore (Q2 FY26: ₹130.66 crore)
  • Profit for the period: ₹428.52 crore (Q2 FY26: ₹415.27 crore)
  • Earnings per share (Basic/Diluted): ₹213.39 (Q2 FY26: ₹195.47)

Key Quantitative Figures - Half Yearly Performance (H1 FY27)

  • Revenue from operations: ₹3,764.69 crore (H1 FY26: ₹3,495.50 crore)
  • Total Income: ₹3,908.12 crore (H1 FY26: ₹3,638.29 crore)
  • Profit before tax: ₹1,182.68 crore (H1 FY26: ₹1,039.06 crore)
  • Total tax expenses: ₹300.71 crore (H1 FY26: ₹257.93 crore)
  • Profit for the period: ₹881.97 crore (H1 FY26: ₹781.13 crore)
  • Earnings per share (Basic/Diluted): ₹415.04 (H1 FY26: ₹367.59)

Cash Flow Highlights (Six months ended September 30, 2026)

  • Net cash from operating activities: ₹658.97 crore
  • Net cash from investing activities: ₹1,159.19 crore
  • Net cash used in financing activities: ₹(1,423.05) crore
  • Dividend paid: ₹1,393.95 crore
  • Cash and cash equivalents at period end: ₹837.44 crore

Expense Breakdown (Q2 FY27)

  • Cost of materials consumed: ₹183.34 crore
  • Purchases of stock-in-trade: ₹835.62 crore
  • Employee benefits expense: ₹175.24 crore
  • Finance costs: ₹5.95 crore
  • Depreciation and amortization: ₹7.55 crore
  • Other expenses: ₹192.85 crore

Capital Structure

  • Paid-up equity share capital: ₹21.25 crore (Face value ₹10 per share)
  • Other equity: ₹4,752.90 crore

Dates and Parties

  • Board meeting date: November 5, 2026 (4:00 PM to 6:30 PM)
  • Statutory auditors: Walker Chandiok & Co LLP
  • Review report date: November 5, 2026
  • Managing Director: Kartik Rajendran (DIN: 09527717)
  • Audit partner: Ashish Gupta (Membership No. 504662)

Auditor's Conclusion

Walker Chandiok & Co LLP issued an unqualified limited review report stating that nothing has come to their attention that causes them to believe that the financial results contain any material misstatement and are in compliance with Regulation 33 requirements.

Additional Information

  • The company operates in a single segment: Pharmaceuticals
  • Previous period figures have been regrouped/reclassified where necessary
  • The financial results were reviewed and recommended by the Audit Committee before Board approval